Showing results (81-90 of 258) with videos related to

Sort By:
Pageof 26
European Journal of Radiology|January 28, 2015
Paired maximum inspiratory and expiratory plain chest radiographs for assessment of airflow limitation in chronic obstructive pulmonary diseaseTakashi Kinoshita, Tomotaka Kawayama, Youhei Imamura, et al.
International Journal of Clinical Oncology|April 7, 2021
First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysisKatsuyuki Hotta, Makoto Nishio, Haruhiro Saito, et al.
International Journal of Clinical Oncology|August 27, 2024
A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutationsKiyotaka Yoh, Koichi Azuma, Hidetoshi Hayashi, et al.
Oncotarget|September 4, 2018
The assessment of correlation and prognosis among 18F-FDG uptake parameters, Glut1, pStat1 and pStat3 in surgically resected non-small cell lung cancer patientsHayato Kaida, Koichi Azuma, Akihiko Kawahara, et al.
Internal Medicine (Tokyo, Japan)|May 16, 2009
Correlation of decreased survival and IL-18 in bone metastasisMasaki Okamoto, Koichi Azuma, Tomoaki Hoshino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2010
Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysisAkihiko Kawahara, Chizuko Yamamoto, Kazutaka Nakashima, et al.
Cancer Chemotherapy and Pharmacology|January 6, 2009
Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiationKoichi Azuma, Tetsuro Sasada, Akihiko Kawahara, et al.
Hellenic Journal of Nuclear Medicine|March 19, 2018
Correlations between dual-phase 18F-FDG uptake and clinicopathologic and biological markers of breast cancerHayato Kaida, Koichi Azuma, Uhi Toh, et al.
Internal Medicine (Tokyo, Japan)|July 10, 2018
Lung Cancer with a Small Cell Carcinoma Component Diagnosed from Pleural Effusion and a Squamous Cell Carcinoma Component Diagnosed from the TumorYoshiaki Zaizen, Takaaki Tokito, Ken Masuda, et al.
Clinical Lung Cancer|December 10, 2021
Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L)Naoki Haratake, Hidetoshi Hayashi, Mototsugu Shimokawa, et al.
Pageof 26